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ABSTRACT 
A diagnosis of metastatic cancer reduces a patient's 5-year survival rate by 
nearly 80% compared to a primary tumor diagnosed at an early stage. While 
gene expression arrays have revealed unique gene signatures for metastatic 
cancer cells, we are lacking an understanding of the tangible physical changes 
that distinguish metastatic tumor cells from each other and from their related 
primary tumors. At the fundamental level, this translates into first characterizing 
the phenotype of metastatic cancer cells in vitro both in 2D – looking at 
morphology and migration – and in 3D – focusing on matrix invasion. While 2D in 
vitro studies have provided insight into the effects of specific environmental 
conditions on specific cancer cell lines, the unique details included in each 
experimental design make it challenging to compare cell phenotype across 
different in vitro platforms as well as between laboratories and disciplines that 
share the goal of understanding cancer. While 3D phenotype studies have 
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employed more standardized and ubiquitous assays, most available tools lack 
the imaging capability and geometry to effectively characterize all factors driving 
3D matrix invasion. 
 
In this work, we present protocols and platforms aimed at addressing the 
problems identified in the tools currently available for studying metastatic cancer 
in vitro. First, we present a 2D study of morphology and migration using widely 
accepted protocols. The study is applied to characterizing phenotypes of three 
breast cancer cell lines with different metastatic organ tropisms. The results show 
that general populations of cells from each of the 3 lines are unique in shape and 
motility despite being derived from the same tumor line and that the observed 
phenotype differences may be related to differences in focal adhesion assembly.  
More broadly, these studies suggest that standardizing phenotype studies using 
commonly available techniques may provide a platform by which to compare 
phenotypic studies across cancer cell types and between research groups to 
investigate tropism-specific cancer phenotypes. We conclude our investigation of 
phenotype with a study of 3D matrix invasion using a novel microfluidic platform. 
The results show that invasion of metastatic breast cancer cells into a 3D type I 
collagen gel is significantly enhanced in the presence of live endothelial cells. In 
applying the model to study cell-cell and cell-matrix interactions driving invasion, 
our platform revealed that, while the fibronectin-rich matrix deposited by 
endothelial cells was not sufficient to drive invasion alone, metastatic breast 
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cancer cells were able to exploit a structural or secreted component of 
energetically inactivated endothelial cell to gain entry into the underlying matrix. 
These findings have important implications for designing drugs targeted at 
preventing cancer metastasis. 
 
The findings in this dissertation reveal significant phenotypic differences in 
metastatic breast cancer cells with different preferences in metastatic target 
organ. In addition, the microfluidic platform reveals novel cell-cell interactions 
driving a key step in the seeding and colonization of a metastatic tumor. 
Collectively, these results reveal important characteristics of metastatic cancer 
cells and their interactions with other cell types during metastasis. These studies 
also provide platforms on which to target or prevent malignant phenotypes and 
cellular interactions in the future. 
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Chapter 1: Introduction and Specific Aims 
1.1 Motivation: Cancer Metastasis and the Metastatic Cascade 
Cancer is one of the leading causes of death in the United States, second only to 
heart disease, and despite decades of cancer research, the average 5-year 
survival rate is only 68%.107 Cancer mortality varies widely across different 
cancer types, but over 90% of cancer deaths, regardless of tumor origin, are 
caused by metastasis.56 Cancer metastasis is the spread of cancer cells from a 
primary tumor to a new tissue in the body. To begin the first stage of the 
metastatic cascade (Fig. 1.1), cancer cells must — through mutation or selective 
pressures in the tumor environment — adopt an invasive phenotype that enables 
their migration through the tumor bulk and toward a blood or lymphatic vessel. 
Once at the vessel, tumor-associated macrophages assist tumor cells in entering 
the vessel, a process referred to as intravasation.105 Intravasated cells are then 
carried through the body suspended in fluid where they exhibit anchorage-
independent survival, a hallmark of transformed cancer cells.39 Cells arrested in 
the vessels may then migrate through the vessel wall into the matrix of the new 
organ, a process referred to as extravasation.17 Extravasation is thought to occur 
in three distinct steps, beginning with arrest in the vasculature followed by tight 
attachment and finally active transmigration through the vessel wall.90 Circulating 
tumor cells become lodged in small arteries and capillaries where they initially 
block flow through the vessel. Soon after arrest in the vasculature, however, the 
cells firmly adhere to one side of the vessel and retract from the opposite side, 
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allowing blood flow to resume. Adhered cells then penetrate the vessel wall to 
invade and colonize a new tumor in the healthy tissue of a new organ.18 Once 
inside the parenchyma of a metastatic target organ, metastatic cancer cells work 
with local macrophages and stromal cells to establish signaling and vascular 
networks to promote and sustain their own growth and colonize a tumor in new 
organ tissue.49 
 
 
Figure 1.1: Progression of a cancer cell through the metastatic cascade. (1) A 
cancer cell migrates through the tumor bulk toward a blood vessel. (2) The cell 
intravasates across the vessel wall and (3) travels through the vasculature 
suspended in blood. (4) Cancer cells arrest in narrow capillaries where they 
initially block fluid flow. (5) Trapped cells eventually retract from one side of the 
vessel and spread out on the capillary wall. (6) Cells transmigrate across the 
endothelial monolayer into the extracellular matrix of a new target organ. 
  
 
1.2 Organ Preference in Metastasis 
In the late 1800s, Stephen Paget observed a non-random preference in 
metastasis of breast tumors and hypothesized that all extravasation is not simply 
due to chance events. His observations led to his development of the "Seed and 
Soil" hypothesis, which suggests that metastatic cancer cells (the "seeds") 
(1) (2) (3) 
(4) (5) (6) 
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extravasate into and grow preferentially within target organs (the "soil") which 
they find most favorable.49 Qualities of target organs that make them suitable for 
certain "seeds" over others remain unclear. It is known that many metastases 
follow the route of circulation from the primary tumor, and tumor cells frequently 
arrest either in nearby lymph nodes or in the microvasculature of nearby organs. 
A common example of this type of metastasis is gastro-intestinal metastasis 
arising from primary tumors in the liver.49 While the likelihood of arrest in the 
vasculature certainly plays a role in many cases of extravasation, this 
observation alone does not explain, for example, bone metastases that 
commonly result from breast and prostate cancer or skin and kidney cancers that 
frequently metastasize to lung tissue. These observations to identification of 
metastatic organ tropism, or organ preference in metastasis, for certain tumor 
cells. 
 
1.3 Characterizing Genetic Differences between Primary and Metastatic 
Tumors 
Regardless of organ tropism, most metastatic tumors are treated with the same 
drugs used to treat the primary tumor.5 The motivation behind this treatment is 
that cells from the metastatic tumors retain a gene expression profile that is 
similar to that of cells from the primary tumor.93 As of 2016, however, Stage IV 
metastatic breast cancer had a 5-year survival rate of only 22%, compared to 
nearly 100% for primary tumors caught Stage I.89 It is clear, then, that the 
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differences in gene expression that do exist between primary and metastatic 
tumors must contribute significantly to the drastic differences in treatment 
outcome. In 2006, Bernards et al. performed microarray analysis to classify 
patients diagnosed with breast cancer according to both tumor gene expression 
profile and prognosis.100 While the study was monumental in uncovering a gene 
expression signature of cells from the primary breast carcinoma that was related 
to poor long-term patient survival, the study did not directly link the signature to 
metastasis or attempt to characterize gene expression of metastatic tumors. 
Massagué et al. turned the focus in gene analysis to the metastatic tumors 
themselves by studying cell lines derived from the invasive human breast 
carcinoma line MDA-MB-231 (MDA-231).61 A lung-specific metastatic 
subpopulation of MDA-231 cells, LM2-4175, was selected by injecting MDA-231 
cells into the tail vein of a rat and harvesting cells from metastatic tumors that 
arose in the rat lung. Transcriptomic microarray analysis of the highly lung-
metastatic cells was compared to that of weakly lung-metastatic populations to 
identify a total of 95 genes whose expression levels were unique to the highly 
lung-metastatic subpopulation. A similar study performed by Massagué et al. 
identified 102 genes whose expression levels were unique to an MDA-231 
subpopulation that was highly bone-metastatic in a mouse model.40 It is clear 
from these studies that there are significant differences in gene expression that 
are characteristic of cells that have completed the metastatic cascade and 
colonized successful metastatic tumors. How these gene signatures are 
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manifested in cell behavior is an important focus of many current in vitro and in 
vivo studies. 
 
1.4 Adaptations that Promote Successful Extravasation and Colonization 
The key to understanding why metastatic cells have a different gene signature 
from the primary tumor is knowing what adaptations enable survival throughout 
the metastatic cascade – specifically, the steps of extravasation and colonization. 
While metastasis is the main cause of death from cancer, it is an inefficient 
process, with few cells from the primary tumor surviving to establish metastases 
in new organs.49 In order to survive metastasis and extravasate, metastatic cells 
must adapt pathways to evade most mechanisms of programmed cell death. 
Akfirat et al. performed immunohistochemistry on metastatic prostate cancer 
cells in a tissue microarray to show that metastatic cells expressed high levels of 
multiple inhibitors of apoptosis proteins (IAPs).2 Previous studies have shown 
that primary prostate tumors also express these IAPs, and that increased 
expression is indicative of metastatic progression.44,45 The study of the metastatic 
lines, however, showed that the IAP expression profile differed from that of the 
parent line.  Furthermore, the expression of specific survival pathways even 
differed between metastatic lines derived from different target organs. 
Specifically, IAPs that were highly expressed in bone-metastases were 
significantly diminished in soft tissue metastases, and vice versa. A likely cause 
of these differences is the metastatic niche microenvironment itself. Though 
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unable to be experimentally proven, it is thought that surface receptors over-
expressed in bone but not soft tissue up-regulate the expression of the IAPs that 
are predominant in bone metastases. Thus, the possible gene expression 
regulation by the metastatic microenvironment itself may alter the cells of 
metastatic lines to impart a growth advantage in the new metastatic niche. 
  
In addition to avoiding apoptosis, metastatic cells must develop adaptations that 
allow for survival and growth within the new metastatic niche. Metastatic cells in 
the brain provide a striking example of this adaptation. Brain tissue metastases 
are significantly more common than primary brain tumors despite the brain 
possessing a significant barrier to infiltrating cells: the blood-brain barrier.55 Not 
only do cancer cells require special mechanisms and molecules in the metastatic 
microenvironment to cross the barrier, but most cancer cells that do pass the 
blood-brain barrier are unable to remodel or assimilate into the new tissue 
environment and ultimately die. Massagué et al. identified two unique 
adaptations of metastatic cancer cells that thrive in the brain metastatic niche.99 
First, an up-regulation of serpin proteins in metastatic cancer cells provides 
protection against the brain stroma itself, in which astrocytes patrol the 
perivascular space to thwart extravasating cancer cells. Second, cancer cell 
expression of L1CAM – a receptor usually expressed only in neurons – allows 
the cells to spread along brain capillaries and co-opt them to promote metastatic 
tumor growth. This work provides a clear example of how metastatic cancer cells 
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develop adaptations that not only provide a general survival advantage but also 
make them fit to flourish in a specific metastatic niche microenvironment.  
 
1.5 Characterizing In Vitro Behavior of Metastatic Cancer Cells in 2D 
In light of the significant differences in gene expression observed for metastatic 
cancer compared to primary tumors, there is considerable interest in 
characterizing the unique behavior of metastatic cancer cells in vitro. 
Chemokinesis – migration of cells in response to soluble signals – is an important 
component of a variety of physiological processes, including inflammation 
response, embryogenesis, and cancer metastasis.77 Jeon et al. designed a 
microfluidic chemotaxis chamber to study the chemotaxis of metastatic breast 
cancer cells in tunable gradients of exogenous epidermal growth factor (EGF). 
EGF is associated with the spread of breast cancer and is a known 
chemoattractant specifically for cancer cells in vivo. By varying the shape and 
input EGF concentration with a novel microfluidic gradient generator, the group 
identified a gradient shape that stimulated optimal migration of breast cancer 
cells in vitro. In true metastasis in vivo, the chemokines related to migration and 
extravasation are produced by cells in the metastatic niche. In a study by 
Takayama et al. metastatic breast cancer cells expressing CXCR-4 receptors 
were induced to migrate toward cells producing the CXCL-12 (the CXCR-4 
ligand). Importantly, it was not just presence of the CXCL-12 but also a gradient 
of CXCL-12 across the breast cancer cells that induced migration. The gradient 
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in this experiment was formed by sink-cells expressing CXCR-7 – a receptor that 
also binds CXCL-12 – located on the opposite side of the breast cancer cells.95 
 
1.6 Characterizing In Vitro Behavior of Metastatic Cancer Cells in 3D 
Building upon simple 2D studies of cancer cell behavior, the development of 
microfluidic models over the past decade has enabled researchers to study 
cancer cell behavior in a 3D geometry that better mimics that of the metastatic 
microenvironment in vivo. For example, Zohar et al. designed a microfluidic 
model to investigate chemokine-mediated extravasation of metastatic breast 
cancer cells into a 3D matrigel substrate mimicking the metastatic niche 
extracellular matrix (ECM). The results showed that local gradients of the 
chemokine CXCL-12 across the endothelial monolayer promoted 
transendothelial migration (TEM) and extravasation of breast cancer cells into the 
matrigel matrix.75 Other microfluidic models have focused on capturing not just 
the geometry but also key components of the biological environment in the 
metastatic niche. Kamm et al. developed a microfluidic device to study breast 
cancer TEM into a bone metastatic niche. The extracellular matrix supporting the 
endothelial monolayer in this model was composed of type I collagen, rather than 
matrigel, and contained osteo-differentiated mesenchymal stem cells. The results 
showed that more breast cancer cells extravasated into the bone-mimicking 
microenvironment compared to a plain collagen gel alone. While this simplified 
model contains only minimal aspects of an in vivo metastatic niche, it served to 
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demonstrate that the biological and chemical components of the metastatic 
microenvironment contribute significantly to cancer cell TEM.12 
 
1.7 Proposed Study of Metastatic Cancer Phenotype 
Current in vitro studies of metastatic cancer have addressed many important 
questions about what drives extravasation and colonization of metastatic tumors. 
From identifying unique metastatic gene signatures to investigating metastatic 
niche cues that influence extravasation, the collective effort of research over the 
last 2 decades has provided a comprehensive study of many critical parts of the 
metastatic cascade. What many current studies lack, though, is a thorough side-
by-side comparison of related metastatic lines, as these differences likely explain 
the drastic disparity in survival for primary and metastatic cancers. In addition, 
the body of current work on metastasis can be enhanced by the development of 
a novel microfluidic platform capable of investigating both structural and soluble 
signal contributions to tissue invasion related to extravasation. 
 
The motivation of this dissertation was to develop in vitro methods and tools to 
more thoroughly characterize important 2D and 3D phenotypes of metastatic 
cancer cells. In addition to providing a novel characterization of the specific 
cancer cells used in the study, the platforms and techniques can be easily 
applied to study other cancer types and even immune and vascular disorders. 
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1.8 Specific Aims 
This dissertation is divided into three specific aims that focus on characterizing 
the morphology, chemokinesis, and matrix invasion phenotypes of metastatic 
cancer cells. This characterization is accomplished through the use of a 
commercially available chemotaxis chamber as well as a novel microfabricated 
model of matrix invasion. 
 
Aim 1: Characterize the morphology of cells from metastatic breast cancer lines 
derived from the same primary tumor. For this aim, we have quantified the area, 
roundness, and actin fiber alignment of breast cancer cells cultured on glass. 
  
Aim 2: Characterize the chemokinesis of cells from 3 related metastatic breast 
cancer lines using a commercially available cell migration chamber. For this aim, 
we have a) designed an experiment to quantify 2D chemokinesis of cancer cells 
seeded on a tissue culture plastic surface and b) investigated the relationship 
between vinculin organization and trends in chemokinesis. 
  
Aim 3: Develop a microfluidic device to investigate invasion of metastatic breast 
cancer cells into a soft extracellular matrix gel. For this aim, we have a) designed 
and fabricated a microfluidic model of type I collagen gel matrix invasion, b) 
investigated the interactions between endothelial cells and cancer cells that 
enhance metastatic cancer cell matrix invasion. 
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 The findings reported in this dissertation provide important insight into the 
significant physical differences between genetically related breast cancer lines 
with different metastatic target organ preference. In addition, the microfabricated 
platform designed to study metastatic cancer matrix invasion can be applied to 
investigate a variety of research questions involving blood vessels, including 
immune cell recruitment in wound healing or atherosclerotic plaque formation. 
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Chapter 2. An In Vitro Comparison of the Morphology of Related Metastatic 
Breast Cancer Cells that Preferentially Metastasize to Different Target 
Organs 
 
2.1 Introduction 
Cancer metastasis is the spread of cancer cells from the primary tumor to a new 
organ tissue. Rather than undergoing random dissemination throughout the 
body, metastatic cancer cells commonly follow trends in metastatic tumor 
colonization thought to represent organ preferences in metastasis. This theory 
was first proposed in the late 1800s, when Stephen Paget observed a predictable 
pattern of metastasis in breast cancer.49 Unique gene expression signatures 
have been derived for cells that preferentially invade a particular metastatic niche 
and are linked to survival advantages in a specific tissue environment. For 
example, brain metastases have up-regulated expression of protease inhibitors 
that protect them from degradation by brain stromal cells.99 Similarly, beta 
hemoglobin is associated with the functions of oxygen transport and metabolism 
and has been shown to defend cancer cells against oxidative stress. The up-
regulated expression of beta hemoglobin has, therefore, been associated with 
improved survival and growth of metastatic cancer cells in oxygen-rich target 
organs, such as the lung and liver.16 
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Despite the evidence for differences in gene expression related to metastatic 
organ tropism, there is insufficient evidence for how these changes in gene 
expression are broadly manifested in altered phenotypes. A major challenge to 
drawing significant conclusions about metastatic cancer cell phenotypes related 
to metastatic tropism from current literature is the wide variety of culture 
substrates and conditions available for cell phenotype studies. For example, 
substrates used in many current in vitro investigations of metastatic cancer cells 
range from tissue culture-treated polystyrene and glass to collagen gels, 
polyacrylamide gels, and even soft elastomers, like polydimethylsiloxane 
(PDMS).46 The culture conditions used for in vitro cancer cell studies yield even 
more variation, as researchers study the effects of extracellular matrix protein 
composition, substrate stiffness, oxygen supply, and chemokine concentrations 
on cancer cell phenotype in order to draw conclusions about cell behavior that 
mimic the native tumor microenvironment.97,76,94,52 For example, Wang et al. grew 
metastatic breast cancer cells on glass coated with type IV collagen in various 
concentrations of epidermal growth factor (EGF) to determine the relationship 
between EGF concentration and cancer cell motility.101 In an in vitro study of 
several glioma lines, Ulrich et al. grew cells in DMEM with 10% calf serum on 
polyacrylamide gels covalently coated with type I collagen to correlate glioma cell 
spread area and migration speed to gel stiffness.98 In a unique in vitro model of 
tumor hypoxia, Acosta et al. studied the growth rate and migration of pancreatic 
adenocarcinoma cells within a microfluidic device consisting of PDMS bonded to 
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tissue culture polystyrene that was designed to deliver spatial oxygen gradients.1 
While these studies provide insight into the effects of specific environmental 
conditions on specific cancer cell lines, the unique details included in each 
experimental design make it challenging to directly compare cell phenotype 
studies across different in vitro platforms and between laboratories.  
 
There are still in vitro cancer studies being performed on standard culture 
substrates, typically glass or plastic. These studies, however, often are narrowly 
focused on one cell line and investigate phenotype in response to cell-type 
specific gene expression.26,66,103 Similar to the research directed at increasing 
platform complexity, it is challenging to extrapolate the results to other metastatic 
cancers in general. To address this problem, we propose an approach of 
phenotypic studies using common and well-studied cell culture protocols and 
substrates, such glass and tissue culture polystyrene, that can be applied to any 
cell type in any lab and will facilitate drawing important conclusions about general 
phenotypes inherent to different cancers. This is of particular interest for 
metastatic cancer, as the understanding of what makes metastatic cancer so 
deadly is still clouded by the lack of consistent in vitro studies on how metastatic 
cancer cells with different organ tropisms compare both to the derived primary 
tumors as well as to related lines with different organ tropisms.  
 
In this aim, we have focused our investigation on the morphology phenotype, as 
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morphology has been shown to correlate to fundamental in vivo cancer cell 
behavior. Common metrics used to quantify morphology of cells are cell area, 
actin fiber alignment, and cell roundness. For cell area, it has been shown that an 
increase in substrate stiffness is related to an increase in spread area for both 
healthy and cancerous mammalian cells.73,68 The change in spread area is 
indicative of a stiffness-dependent reorganization of matrix adhesion proteins on 
the cell membrane.70 Specifically, it has been shown that a decrease in spread 
area was related to an increase in migration and invasion in non-transformed 
human cells.48 This trend was also observed in rat prostate cancer cells, where 
Crooke et al. found that an decrease in spread area was correlated with an 
increase in metastatic potential.23 While cell area can reveal trends in migration 
and metastatic potential, actin fiber alignment and cell roundness are closely 
related to the function of a cell in its native environment. Specifically, actin fibers 
tend to be more aligned in cells that are frequently under tensile stress, such as 
lungs and muscles.30 Regarding cell roundness, cells that are more elongated 
are generally well suited for contraction.50 Characterizing spread area, fiber 
alignment, and cell roundness of primary and metastatic cancer cells may reveal 
significant differences that distinguish cells with different metastatic target organ 
preferences. 
 
It is clear from observed differences in gene expression that metastatic cancer 
cells develop adaptations for survival in a preferred metastatic niche. These 
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differences in gene expression are manifested in changes in phenotype that 
make metastatic tumors different from not only the primary tumor but also 
metastatic tumors in different organs. The focus of this study is on quantifying the 
physical differences in morphology between 3 breast cancer cells lines with 
different metastatic target organs. The first line, MDA-MB-231 (MDA-231) was 
established using cells collected from pleural effusions in a patient with 
metastatic breast cancer.6 These cells have intravasated but have not 
preferentially extravasated into a specific organ.  To generate the two other lines 
used in this study, MDA-MB-231 were injected into the left ventricle or tail vein of 
a rat, and the BoM-1833 and LM2-4175 lines were subsequently harvested from 
spontaneous bone and lung metastases, respectively.61,40 These lines exhibit a 
true experimentally derived metastatic organ tropism. Cell morphology was 
studied by growing cells on glass coated with type I collagen. Cells were fixed 
and stained for filamentous actin and nuclear stains for quantification of cell area, 
roundness, and actin filament alignment. Our results suggest that in vitro 
phenotype studies using common culture substrates and a standard set of 
relevant metrics may provide an important foundation for drawing conclusions 
about the hallmark in vitro characteristics shared by certain organ metastases. 
This work also highlights the utility of well-characterized and universally available 
culture substrates to generate results that can be easily translated across 
cancer-focused labs and research disciplines. 
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2.2 Methods 
Cell Culture and Reagents 
The invasive breast cancer line MDA-MB-231 (MDA-231; ATCC, Manassas, VA) 
and its bone-metastatic and lung-metastatic derivatives, BoM-1833 and LM2-
4175 (a gift from Dr. Joan Massagué at Memorial Sloan Kettering Cancer Center, 
NY) were cultured in phenol red-free Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with antibiotics (Gibco, Grand Island, NY) and 10% heat-
inactivated fetal bovine serum (H-I FBS; Invitrogen, Carlsbad, CA; 56ºC for 
30min)). Cells were cultured at 37ºC and 5% CO2 on plasma-treated tissue 
culture dishes and were detached from the surface using 0.05% trypsin (Gibco). 
 
Characterizing Cell Morphology 
Morphology of MDA-231, BoM-1833, and LM2-4175 cells was quantified on glass 
coverslips coated with 5µg/cm2 type I collagen in 0.2M glacial acetic acid (Sigma-
Aldrich, St. Louis, MO) for 1hr at room temperature in 6-well plates prior to cell 
seeding. MDA-231, BoM-1833, and LM2-4175 cells were serum-starved for 24hr 
in 0.1% BSA-DMEM and re-suspended in DMEM with 10% H-I FBS at a 
concentration of 5x105 cells/mL. 50,000 cells were seeded onto the collagen-
coated glass and incubated for 2hr at 37ºC. Equal numbers of cells were added 
to 3 unique glass coverslips for each cell type. Wells containing cells and 
substrates were filled with 10% H-I FBS-DMEM and incubated at 37ºC for 24hr. 
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Following incubation, cells were fixed to the glass substrates and were stained to 
visualize cellular nuclei and filamentous actin. In brief, cells were washed with 1X 
phosphate-buffered saline (PBS) and fixed in 4% paraformaldehyde in PBS for 
15min at room temperature. After washing with PBS, the cell membranes were 
permeabilized with the addition of 0.1% Triton X-100 for 10min at room 
temperature. After permeabilization and washing, the cells were incubated with 
2µg/mL Hoechst 33342 (Molecular Probes, Eugene, OR) and a 1:40 dilution of 
fluorescein isothiocyanate-conjugated phalloidin (FITC-phalloidin) stock in 1% 
BSA-PBS for 1hr at room temperature. Images were captured using an Olympus 
IX81 fluorescence microscope with DAPI (4',6-diamidino-2-phenylindol) and FITC 
filter sets. FITC-phalloidin images were imported into ImageJ. Manual traces of 
representative cells were used to compute average cell area and roundness. 
Area was computed directly from the measurement tool in ImageJ and scaled by 
the camera pixel dimensions. Roundness was taken as the ratio of the square of 
the cell perimeter to the cell area and scaled by a factor of 1/4π. A perfect circle 
has a roundness of 1, while irregularly shaped objects have a roundness greater 
than 1. Actin fiber alignment was also measured from the FITC-phalloidin cell 
traces using the ImageJ FibrilTool macro.13 The tool reports an anisotropy index 
in which perfectly aligned fibers have an index of 1, perfectly disordered fibers 
have an index of 0, and moderately disordered fibers have an index between 0 
and 1. 
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Statistical Analysis 
All data was analyzed for significance using Matlab to compute an F test for 
equality of variance as well as a two-tailed Student's t test (based on the results 
of variance equality) with significance cutoffs of P = 0.01 or P = 0.05. Equal 
numbers of each cell type were seeded on 3 unique glass substrates resulting in 
3 experimental replicates for each cell type. For statistical analysis, cells from 
each type were pooled from all 3 substrates, resulting in N values representing 
the total number of cells analyzed from all substrates for each cell type. 
 
2.3 Results 
Related Metastatic Breast Cancer Cell Lines Appear Morphologically 
Different on Glass Substrates 
Cells from the metastatic MDA-231 line along with cells from the experimentally 
derived BoM-1833 and LM2-4175 cell lines were fixed on glass substrates and 
treated with filamentous actin (green) and nuclear (blue) stains for studying cell 
morphology. Images of representative cells from each condition (Fig. 2.1) show 
that average populations of cells from each line appear qualitatively different 
despite identical seeding conditions and glass substrates. Cells from the bone-
metastatic BoM-1833 line (Fig. 2.1b) present with a more circular perimeter 
compared to cells from the lung-metastatic LM2-4175 line (Fig. 2.1c), which 
appear much more narrow and elongated. Cells from the MDA-231 line (Fig. 
2.1a), however, were more heterogeneous in shape, with some cells appearing 
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circular and other cells appearing more elongated. 
 
Figure 2.1: Staining for cancer cell morphology. (a) MDA-231, (b) BoM-1833, and 
(c) LM2-4175 cells stained with FITC-phalloidin (green) for filamentous actin and 
Hoechst nuclear stain (blue) to distinguish unique cell bodies. Cells were fixed on 
glass microscope slides coated with 5µg/cm2 type I collagen. 
 
Related Metastatic Breast Cancer Cell Lines Differ in Cell Area, Roundness, 
and Actin Fiber Alignment on Glass Substrates 
The observed differences in cell shape on glass were quantified by tracing cell 
bodies in ImageJ to compute average cell area, roundness and fiber alignment. A 
total N of 124 cells for MDA-231, 188 cells for BoM-1833, and 127 cells for LM2-
4175 were traced for analysis. Fixed on identical glass substrates, cell spread 
area (Fig. 2.2a) was significantly larger in cells from the metastatic lines with 
organ tropisms to either lung (985.2µm2 +/- 27.2) or bone tissue (985.6µm2 +/- 
55.4) compared to cells from the original MDA-231 line (759.2µm2 +/- 36.9; BoM-
1833 v. MDA-231: P = 0.012; LM2-4175 v. MDA-231: P = 9x10-6). The average 
spread areas of the BoM-1833 and LM2-4175 cells were not significantly different 
from each other, however. From the study of cell roundness (Fig. 2.2b), it was 
determined that cells from the lung metastatic LM2-4175 line were significantly 
more elongated (3.00 +/- 0.115) than cells from BoM-1833 line (1.89 +/- 0.057; P 
(a) (b) (c)
20µm
MDA 231 BoM 1833 LM2 4175
20µm20µm
Figure 1. Staining for cancer cell morphology. (a) MDA-231, (b) BoM-1833, nd (c) LM2-4175 cells stained with FITC-phalloidi
(green) for filamentous actin and Hoechst nuclear stain (blue) to distinguish unique cell bodies. Cells were fixed on glass
microscope slides coated with 5µg/cm2 type I collagen.
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= 2.9x10-8). Average cell roundness in the MDA-231 cell line (2.31 +/- 0.14) fell 
between that of the LM2-4175 cells and the BoM-1833 cells, but the mean was 
not significantly different from that of either metastatic line. The trend in actin 
fiber alignment (Fig. 2.2c) showed a similar trend; actin fibers in LM2-4175 cells 
were significantly more aligned (0.230 +/- 0.011) than those in BoM-1833 cells 
(0.172 +/- 0.007; P = 0.033). Average fiber alignment in MDA-231 (0.20 +/- 0.01) 
cells fell between that of the LM2-4175 cells and the BoM-1833 cells, though the 
means were not significantly different. These quantitative results confirm the 
qualitative observations that these three related breast cancer lines with different 
metastatic organ tropisms differ in terms of their morphology on glass. 
 
Figure 2.2: Quantifying cancer cell morphology. Average cell area, roundness, 
and actin fiber anisotropy index (AI) of MDA-231, BoM-1833, and LM2-4175 cells 
cultured for 24hr on glass coated with 5µg/cm2 type I collagen. Average values 
for 124 MDA-231 cells, 188 BoM-1833 cells, and 127 LM2-4175 cells compiled 
from 3 independent glass substrates for each cell type. Error bars indicate 
standard error of the mean; *, P < 0.05; **, P < 0.01 by Student’s t test. (a) Area 
was calculated in ImageJ from manual tracings of cell perimeters. (b) Roundness 
was computed as the ratio of the square of the cell perimeter to the cell area and 
scaled by a factor of 1/4π. (c) Actin fiber anisotropy index (AI) was determined 
using the ImageJ FibrilTool macro. 
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Figure 2. Quantifying cancer cell morphology. Average cell area, roundness, and actin fiber anisotropy index (AI) of MDA-231,
BoM-1833, and LM2-4175 cells grown for 24hr on glass coated with 5µg/cm2 type I collagen. Average values for 124 MDA-231
cells, 188 BoM-1833 cells, and 127 LM2-4175 cells compiled from 3 independent glass substrates for each cell type. Error bars
indicate standard error of the mean; *, P < 0.05; **, P < 0.01 by Student’s t test. (a) Area was calculated in ImageJ from manual
tracings of cell perimeters. (b) Roundness was computed as the ratio of the square of the cell perimeter to the cell area and scaled
by a factor of 1/4π. (c) Actin fiber anisotropy index (AI) was determined using the ImageJ FibrilTool macro.
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2.4 Discussion 
Much of the current in vitro biomaterials-based cancer literature is invested in 
building and fine-tuning biomimetic models of the in vivo tumor 
microenvironment. While these results are interesting, the numerous variations in 
culture platform and conditions make it nearly impossible to compare results 
between different cancer cell lines and publications from different research 
groups. In this study, we cultured MDA-MB-231 breast cancer cells as well as 
lung and bone-metastatic derivatives on commonly used and ubiquitous culture 
platforms to identify significant differences in fundamental morphology 
phenotypes. By simplifying the in vitro platform design and restricting analysis to 
pre-defined relevant metrics, our methods revealed important differences in in 
vitro morphology for three related cell lines with different metastatic tropisms in 
vivo.  
 
The morphology analysis of cells fixed to glass revealed a smaller spread area of 
the MDA-231 cells compared to the lung and bone-metastatic derivatives. As 
mentioned previously, other literature has correlated cell spread area in vitro with 
metastatic potential, which is the likelihood of cells to colonize a metastatic tumor 
in vivo.104 In the context of this observation, the morphology results presented in 
this work might indicate differences in metastatic potential between breast cancer 
cell lines with different metastatic organ tropisms. While the average spread 
areas of the bone and lung metastatic lines were not statistically different, 
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analysis of cell shape indicated that cells from the lung-metastatic line were more 
elongated with more highly aligned actin fibers compared to the bone-metastatic 
line. The metrics of roundness and fiber alignment have been correlated with a 
range of in vivo cell functions in literature including motility, contractility, and 
invasiveness.88,71,54 While these morphology studies do not aim to replicate or 
draw concrete conclusions about cell function in vivo, the observed differences in 
morphology on standard glass substrates may indicate inherent phenotypic 
differences in these related breast cancer cell lines with different metastatic 
tropisms. 
 
In summary, the results presented in this work show how universally available 
platforms, cell culture protocols, and immunostaining methods can provide a 
clear and powerful comparison of cancer cell morphology in vitro. This 
investigation was applied to elucidate differences between related metastatic 
breast cancer lines with different metastatic tropisms. Combined with the 
knowledge that unique gene signatures exist for cancer lines with different organ 
tropisms, the observed differences in morphology suggest important differences 
in cell behavior that may be related to the significant differences in treatment 
outcome for metastatic cancers.56 In addition, by reducing the variation in in vitro 
model design and using standard culture platforms, it may be possible to 
compare and share results between cancer phenotype studies to develop distinct 
phenotype identities for specific cancers, similar to the reported metastatic gene 
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signatures. The future direction of this work involves applying these methods to 
studying breast cancer lines with organ tropisms other than lung and bone as 
well as metastatic lines derived from primary tumors other than breast cancer to 
identify comprehensive and novel trends in in vitro cancer cell morphology. 
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Chapter 3. An In Vitro Comparison of the Chemokinesis of Related 
Metastatic Breast Cancer Cells that Preferentially Metastasize to Different 
Target Organs 
 
3.1 Introduction 
Regardless of tumor origin, 90% of cancer-related deaths are due to 
metastasis.56 In fact, a diagnosis of Stage IV metastatic cancer is linked to an 
average 5-year survival rate of only 22%, while the 5-year survival rate for 
diagnosis of a Stage I primary tumor is almost 100%.89 Despite this enormous 
disparity in survival outcome, most metastatic tumors are treated with the same 
drugs used to treat the primary tumor due to the fact that metastatic tumors retain 
a similar gene expression profile to that of the primary tumor.93 Recent work, 
however, has delved into the differences between primary and metastatic tumors 
in an effort to identify unique and treatable targets for metastatic cells. 
Specifically, some studies have identified unique gene expression signatures of 
metastatic tumors that endow cells with advantages for survival and tumor 
colonization within a metastatic target organ. For example, gene expression 
analysis of metastatic prostate cancer cells revealed an up-regulated expression 
of proteins to inhibit apoptosis compared to cells from the primary tumor.2 A 
similar study on the Raf-1 kinase inhibitor protein (RKIP) found that expression 
was diminished in many primary tumors but completely absent in metastatic 
tumors. In this study, Bonavida et al. linked the absence of RKIP to a down-
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regulation of death receptors in metastatic cells that enhances evasion of 
immune surveillance.10 
  
Many of the gene expression adaptations of metastatic cancer cells result in 
increased migration and tissue invasion, properties that can be observed in vitro 
by studying differences in 2D chemotaxis.9,23 In comparing 2D chemotaxis of 
metastatic and primary cells, Cai et al. found that spinal metastatic cells derived 
from the non-small cell lung cancer line A549 were significantly more migratory 
and invasive than cells from the primary A549 line.15 Bielenberg et al. found a 
similar result with metastatic prostate cancer cell lines established through 
repeated selection of lymph node metastases in a mouse model.9 The metastatic 
derivatives were significantly more migratory and invasive than the primary 
human prostate cancer line, DU145. A clear comparison of paired primary and 
metastatic tumor lines, as presented in these studies, provides convincing 
evidence for adapted migration phenotypes that may confer general survival 
advantages on metastatic tumors cells. Extending this type of study to include 
multiple metastatic cell lines side-by-side, then, may identify significant 
differences in migration and invasion behavior that could be attributed to organ 
preference in metastasis. 
 
The challenge in performing side-by-side comparisons of related metastatic lines 
is finding appropriate lines to compare. In one study, Smalley et al. compared 
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two human melanoma cell lines that had been selected for preferential 
metastasis to lung tissue in a mouse model. Though derived from different 
primary melanoma tumors, both metastatic lines showed a similarly increased 
resistance to treatment with migration inhibitors compared any of the early-stage 
melanoma lines examined in the same study. While the results suggest a general 
consistency in behavior across different metastatic melanoma lines compared to 
primary melanoma, the study still only considers preferential metastasis to one 
target organ.87 Alexaki et al. designed a similar but more robust study that 
compared the Matrigel invasion properties of 8 human melanoma lines in total. 
Four of the lines were derived from different primary melanoma tumors, and the 
remaining 4 lines were derived from metastatic lesions harvested from human 
lymph tissue or from lung tumors that arose in a mouse model following tail vein 
injection of human melanoma cells. On average, the 4 metastatic lines were all 
more invasive than the primary tumor lines. Though the means of each of the 4 
metastatic lines appears quite different, the work did not describe or explain the 
significance of differences in this population.4  
 
Collectively, these studies suggest that a conclusive comparative study of 
different metastatic lines requires a panel of metastatic lines derived from the 
same primary tumor but with different metastatic target organ preference. Such a 
panel was presented by the Massagué group and consisted of multiple 
genetically related metastatic breast cancer sublines that demonstrated 
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preferential metastasis to either lung or bone tissue in a mouse model. The 
parental cell line used to derive the sublines, MDA-MB-231 is a commonly 
studied line established from pleural effusions in a patient with metastatic breast 
cancer.61 The gene expression profiles in the original studies highlight 102 and 
95 genes with expression levels that are uniquely up- or down-regulated in the 
bone and lung metastatic sublines, respectively, when compared to the parental 
MDA-MB-231 line. These distinctions are especially notable considering the 3 
lines show largely similar expression of genes constituting the traditionally 
accepted Rosetta poor-prognosis gene signature.40,61 Even more, these sublines 
provide a foundation on which to perform side-by-side in vitro comparisons of 
metastatic breast cancer lines with different target organ preference to identify 
target organ-specific adaptations in migration and invasion phenotype.  
 
In a study published recently after the derivation of these metastatic sublines 
lines, Ohri et al. applied a matrigel invasion assay to compare the gel invasion 
properties of the MDA-MB-231 lines and two of its bone- and lung-metastatic 
derivatives: BoM-1833 and LM2-4175. The results showed that the lung-
metastatic subline was significantly more invasive than either the bone-
metastatic subline or the parental MDA-MB-231 line, with the MDA-231 cells 
showing lower invasion than either subline. This difference in invasiveness was 
shown to correlate with expression levels of procathepsin D, a glycoprotein 
known to play a role in breast cancer progression.69 In a related study, the same 
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group showed that while approximately 100 genes had been identified through 
gene expression analysis to be unique to either bone or lung metastases, only 16 
of the detected mRNA differences were actually manifested in differences in 
expressed protein, a list which includes procathepsin D. As proteins are 
responsible for cellular interactions and basic function, these results emphasize 
the importance of extending characterization beyond basic gene expression 
through mRNA synthesis to understand physical differences in cell function for 
genetically related tumors with different target organ metastasis.84  
 
The considerably limited supply of genetically related cancer lines from different 
metastatic target organs has resulted in little momentum in the effort to correlate 
in vitro migration phenotype and protein expression with metastatic organ 
tropism. We believe that a thorough characterization of important in vitro 
differences in the existing MDA-231 metastatic derivatives, then, may build a 
compelling case for research efforts to derive panels of metastatic lines for other 
cancers. In contributing to this case, we present a novel comparison of the in 
vitro chemokinesis behavior of the MDA-231, BoM-1833, and LM2-4175 lines, as 
chemokinesis is a critical component of cell migration leading to metastatic 
cancer.77 Chemokinesis was studied in a uniform condition of DMEM with 5% 
fetal bovine serum in a commercially available chemotaxis chamber made of 
tissue culture polystyrene. To investigate the mechanism behind observed 
differences 2D chemokinesis, we looked more closely at the way the 3 cell lines 
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interacted with the culture surface. Specifically, we stained cells for the vinculin 
protein, which links the actin cytoskeleton to integrin membrane proteins that 
form focal adhesions with extracellular matrix proteins.35 
 
The results revealed significant differences in the migration of the MDA-231, 
BoM-1833, and LM2-4175 lines. In addition, vinculin staining revealed significant 
qualitative differences in the arrangement of focal adhesions, suggesting that 
cells from the 3 lines interact differently with identical culture substrates and that 
focal adhesion organization may be responsible for the observed differences in 
migration. These studies suggest that metastatic target organ preference may 
manifest itself in physical and measurable differences in in vitro migration 
metrics. Future work to characterize a broader panel of metastatic lines in vitro 
may facilitate the characterization of migration behaviors characteristic of target 
organ preference, similar to the work that has been done for gene expression. 
 
3.2 Methods 
Cell Culture and Reagents 
The invasive breast cancer line MDA-MB-231 (MDA-231; ATCC, Manassas, VA) 
and its bone-metastatic and lung-metastatic derivatives, BoM-1833 and LM2-
4175, were cultured in phenol red-free Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with antibiotics (Gibco, Grand Island, NY) and 10% heat-
inactivated fetal bovine serum (H-I FBS; Invitrogen, Carlsbad, CA; 56ºC for 
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30min)). Cells were cultured at 37ºC and 5% CO2 on plasma-treated tissue 
culture dishes and were detached from the surface using 0.05% trypsin (Gibco). 
 
Migration on Type IV Collagen-Coated Tissue Culture Plastic 
Migration of the MDA-231, BoM-1833, and LM2-4175 cells was studied using 
Ibidi 3D Chemotaxis Chambers (Ibidi, Planegg/Martinsried, Germany)) coated 
with type IV collagen. Cells were stained with 10µM CellTracker Green CMFDA 
(Molecular Probes, Eugene, OR) prior to use in experiments. 17,500 cells in 
DMEM containing 0.5% FBS were added to the Ibidi migration chambers and 
incubated for 30min at 37ºC. Cell migration was studied in a solution of 5% FBS 
in serum-free DMEM. Migration chambers were imaged every 5min for 3hr using 
a Zeiss AxioVert S100 microscope through a green fluorescent protein (GFP) 
filter set in a microscope enclosure that maintained conditions of 37ºC and 5% 
CO2 for the duration of the experiment. For added simplicity and translatability, 
the experimental protocol aimed to equate cell seeding method rather than the 
final number of attached cells across cell types. For the cells in each population 
that did attach and migrate, cell paths were automatically tracked from the 
fluorescent time-lapse images using the ImageJ plugin TrackMate. Cells tracks 
were eliminated from the study if they merged with another cell track during the 
experiment. For the remaining unique, non-overlapping cell tracks, cell motility 
was defined as having a net displacement of 12µm (approximately one cell 
diameter) in 3hr, and non-motile cells were removed using programs written in 
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Matlab. Percent motility (percentage of motile cells out of total cells automatically 
tracked), net displacement (absolute value distance between starting and ending 
position), and directionality (ratio of net displacement to total cell trajectory) were 
quantified in MATLAB®. Directionality values range from 0 to 1, with 0 indicating 
totally random motion, and 1 indicating migration purely in a straight line. 
 
Immunostaining for Vinculin in Metastatic Breast Cancer Cells Fixed to 
Glass 
Cancer cells from the MDA-231, BoM-1833, and LM2-4175 lines were seeded on 
glass coverslips coated with 5µg/cm2 type I collagen as described previously in 
methods to study morphology. After incubation at 37ºC for 24hr, cells were 
washed with PBS and fixed in 4% paraformaldehyde (PFA) in PBS for 12min at 
room temperature. Coverslips were washed thoroughly with PBS, and cell 
membranes were permeabilized with the addition of 0.1% Triton X-100 for 10min 
at room temperature. Following fixation and permeabilization, coverslips were 
washed with PBS and incubated in a blocking solution of 5% BSA-PBS 
overnight. The blocking solution was replaced with a 1:400 dilution of primary 
vinculin antibody (Sigma-Aldrich, St. Louis, MO) in 5% BSA-PBS and stored at 
4ºC for 18hr. Primary antibody was removed with a PBS wash, and cells were 
stored in a 5% BSA-PBS blocking solution for 8hr at 4ºC. Blocking solution was 
then replaced with a solution containing 2µg/mL Hoechst 33342 (Molecular 
Probes, Eugene, OR) along with a 10µg/mL dilution of Alexa Fluor 488-
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conjugated secondary antibody was applied (Invitrogen, Carlsbad, CA). 
Antibody-labeled devices were stored at 4ºC in PBS and imaged using an 
Olympus FV1000 scanning confocal microscope with 405 and 488 nm excitation 
lines. 
 
Statistical Analysis 
All data was analyzed for significance using Matlab to compute an F test for 
equality of variance as well as a two-tailed Student's t test (based on the results 
of variance equality) with significance cutoffs of P = 0.01 or P = 0.05. For the cell 
migration studies, equal numbers of cells were added to 3 unique Ibidi 3D 
Chemotaxis Chambers, resulting in 3 experimental replicates for each cell type. 
Rather than pooling all the individual cells in these studies, however, migration 
was quantified for the cell populations in each separate device, resulting in an N 
value of 3 representing the 3 experimental replicates for each cell type. 
 
3.3 Results 
Metastatic Breast Cancer Cells with Different Metastatic Tropisms Follow 
Different Paths of Migration on Tissue Culture-Treated Plastic 
Cells from each of the three breast cancer lines were seeded on the tissue 
culture-treated plastic surface of Ibidi 3D Chemotaxis Chambers and allowed to 
migrate for 3hr in DMEM with 5% FBS. A plot of the cell paths (Fig. 3.1) for a 
selection of 30 representative cells from each cell type reveals significant 
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qualitative differences in the migration of cells from the 3 related breast cancer 
lines with different metastatic organ tropisms. Paths were superimposed on the 
same plot and normalized so that all tracks began at the origin. LM2-4175 cell 
paths (Fig. 3.1c) extended the farthest from respective starting positions over the 
course of the experiment while cells paths of MDA-231 (Fig. 3.1a) and BoM-1833 
cells (Fig. 3.1b) remain closer to the starting positions. The paths of the BoM-
1833 cells, however, appear more dense and exploratory about the starting 
positions compared to MDA-231 cell paths. 
 
Figure 3.1: Chemokinesis of metastatic breast cancer cells. Automatically tracked 
paths of MDA-231 (a), BoM-1833 (b), and LM2-4175 (c) cells in 5% fetal bovine 
serum (FBS) in Dulbecco’s Modified Eagle’s Medium (DMEM) in the Ibidi 
Chemotaxis Chamber. Cells were seeded in 2D and allowed to migrate on the 
plastic migration chamber surface. Each plot represents data from 30 cells. 
 
Metastatic Breast Cancer Cells with Different Metastatic Tropisms Differ in 
Motility and Net Displacement but Show Similar Directionality on Tissue 
Culture-Treated Plastic 
Differences in migration paths for each cell type were quantified by computing 
percent motility, net displacement, and directionality. The 12µm motility cutoff 
(a) (b) (c)
µm µm
µm µm µm
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-60
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Figure 3. Chemokinesis of metastatic breast cancer cells. Automatically tracked paths of MDA-231 (a), BoM-1833 (b), and LM2-4175
(c) cells in 5% fetal bovine serum (FBS) in Dulbecco’s Modified Eagle’s Medium (DMEM) in the Ibidi Chemotaxis Chamber. Cells
were seeded in 2D and allowed to migrate on the plastic migration chamber surface. Each plot represents data from 30 cells.
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applied to automatically tracked cells and non-overlapping cell tracks yielded a 
total of 65 MDA-231 cells, 197 BoM-1833 cells, and 237 LM2-4175 cells for 
comparing migration. The results show that the percentage of motile cells (Fig. 
3.2a) was highest in LM2-4175 (56.7% +/- 3.0) compared to both BoM-1833 
(33.4% +/- 5.4, P = 0.02) and MDA-231 cells (37.8% +/- 2.4, P = 0.01). Net 
displacement (Fig. 3.2b) followed a similar trend. LM2-4175 cells (26.3µm +/- 
0.8) showed the largest net displacement compared to cells from both the BoM-
1833 (21.7µm +/- 0.7, P = 0.03) and MDA-231 lines (20.9µm +/- 1.5, P = 0.02). 
Regarding directionality (Fig. 3.2c), though the means varied (MDA-231: 0.32 +/- 
0.02, BoM-1833: 0.24 +/- .03, LM2-4175: 0.28 +/- 0.01), none of the three cells 
types were determined to be statistically different from one another. Collectively, 
these results confirm and expand upon the qualitative observations drawn from 
the cell path tracks: the three metastatic breast cancer lines differ in migration 
behavior with respect to motility and displacement but also retain some similarity 
in the directionality of their migration. 
 
Figure 3.2: Migration of MDA-231, BoM-1833, and LM2-4175 cells in a uniform 
solution of 5% FBS in DMEM. Three migration parameters were quantified for 
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Figure 4. Migration of MDA-231, BoM-1833, and LM2-4175 cells in a uniform solution of 5% FBS in DMEM. Three
migration parameters were quantified for each cell type based on 180min time-lapse experiments. (a) Motility is
calculated as the percentage of cells that mig ated more th n 12μm in 180min. (b) Net displac ment is measured as the
average displacement of all motile cells in each condition. (c) Directionality is computed as the ratio of net cell
displacement to total cell trajectory. A directionality of 1 indicates migration in a straight line. The total number of cells
analyzed are 65, 197, and 237 cells compiled from 3 independent devices each for MDA-231, BoM-1833, and LM2-
4175 cells, respectively. Error bars indicate standard error of the mean; *, P < 0.05; **, P < 0.01 by Student’s t test.
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each cell type based on 180min time-lapse experiments. (a) Motility is calculated 
as the percentage of cells that migrated more than 12μm in 180min. (b) Net 
displacement is measured as the average displacement of all motile cells in each 
condition. (c) Directionality is computed as the ratio of net cell displacement to 
total cell trajectory. A directionality of 1 indicates migration in a straight line. The 
total number of cells analyzed are 65, 197, and 237 cells compiled from 3 
independent devices each for MDA-231, BoM-1833, and LM2-4175 cells, 
respectively. Error bars indicate standard error of the mean; *, P < 0.05; **, P < 
0.01 by Student’s t test. 
 
Metastatic Breast Cancer Cells with Different Metastatic Tropisms Differ in 
Organization of Vinculin-Containing Focal Adhesions on Glass Substrates 
Vinculin staining revealed qualitative differences in focal adhesion distribution 
between representative cells from the 3 related breast cancer lines. In cells from 
the BoM-1833 line (Fig. 3.3b), vinculin is well-distributed not only along the 
periphery of the cells but also throughout the cell-substrate interface. The lung 
metastatic LMB-4175 cells (Fig. 3.3c) show a different vinculin distribution, with 
small and sparse focal adhesions concentrated at the end of a dog-bone-like 
morphology. Compared to either of the organ-specific metastatic derivatives, 
representative MDA-231 cells (Fig. 3.3a) showed a much wider variety of vinculin 
distribution. A portion of MDA-231 cells contain vinculin-containing focal 
adhesions distributed around the perimeter, similar to the BoM-1833 cells, while 
others showed vinculin concentrated at opposite ends of a more elongated cell 
similar to LM2-4175 cells. 
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Figure 3.3: Staining for vinculin. (a) Confocal images of representative cells from 
MDA-231, (b) BoM-1833, and (c) LM2-4175 lines stained for the vinculin protein 
(green) in focal adhesions. Cell nuclei visualized with Hoechst (blue). Cells were 
fixed on glass microscope slides coated with 5µg/cm2 type I collagen. Example of 
distinct focal adhesions indicated with yellow arrows. Scale bars: 25μm. 
 
3.4 Discussion 
Despite known differences in gene expression between metastatic tumors 
colonized in different organs, comparatively little investigation has been done to 
determine differences in the physical migration or invasion behavior in cells 
harvested from these tumors. In this work, we have identified significant 
differences in relevant migration metrics between 3 metastatic breast cancer 
lines derived from the same human breast tumor. Our results are in agreement 
with previous reports on trends in in vitro matrix invasion of these 3 lines and 
build a case for future work to derive and characterize more extensive panels of 
related metastatic lines. 
 
Our study of cancer cell migration on tissue culture plastic in a commercially 
available migration platform revealed significant differences in chemokinesis 
between the three breast cancer cell lines. Compared to the parent MDA-231 line 
and the bone-metastatic BoM-1833 line, the lung-metastatic LM2-4175 cell line 
(a) (b) (c)
25μm
MDA-231 BoM-1833 LM2-4175
Figure 5. Staining for vinculin. (a) Confocal images of representative cells from MDA-231, (b) BoM-1833, and (c) LM2-4175
lines stained for the vinculin protein (green) in focal adhesions. Cell nuclei visualized with Hoechst (blue). Cells were fixed on
glass microscope slides coated with 5µg/cm2 type I collagen. Example of distinct focal adhesions indicated with yellow arrows.
Scale bars: 25μm.
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had the highest percentage of motile cell; these cells also migrated the farthest 
from their starting positions over the course of the time-lapse observation. 
Regarding directionality, while the means varied, the differences were not 
statistically significant between any of the cell lines. Similarities in migration 
behavior in these cell lines are expected, however, as the BoM-1833 and LM2-
4175 lines are both experimentally derived from the MDA-231 line. In addition, 
the lines are known to possess similar expression levels of genes constituting 
Rosetta-type poor prognosis signature, some of which are linked to directional 
migration.61,57 Chemokine-induced migration is known to be a critical and 
fundamental component of cancer metastasis in vivo.78,14 Thus, the significant 
differences in motility and net displacement on tissue culture plastic presented in 
this work may suggest differences in migration involved in cancer progression for 
breast cancer cell lines with different metastatic tropisms. 
 
In evaluating the mechanism behind the observed differences in phenotype, we 
determined that the distribution of vinculin-containing focal adhesions is different 
between representative cells from each of the 3 breast cancer lines. It is known 
that focal adhesions function to link the cell membrane to proteins on a substrate 
surface; as a result, vinculin expression and distribution are known play a role in 
both cell spreading and migration.35,19,91 In studying focal adhesions in cancer 
specifically, it has been shown that a reduction in focal adhesions is linked to 
increased migration and metastasis.51 This same trend is observed in our work, 
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which revealed that the highly motile LM2-4175 subline qualitatively has the 
fewest focal adhesions throughout the cell-substrate interface compared to either 
the BoM-1833 or MDA-231 lines, suggesting vinculin distribution as a mechanism 
for the observed differences in phenotype. The impact of this mechanistic 
vinculin study is particularly evident when considering the published gene 
expression profiles for these cell lines. Gene expression analysis tells us that the 
3 lines have similar overall expression levels of vinculin, but our phenotypic in 
vitro studies reveal important differences in actual vinculin organization and 
distribution in culture.40 Thus, imaging vinculin distribution, as we have done in 
this study, not only helps elucidate a mechanism of the observed differences in 
phenotype between 3 related breast cancer lines but also builds on the 
knowledge gained from gene expression analysis to develop a more thorough 
characterization of cancer cells with preferential organ metastasis. 
 
In summary, the results presented in this aim demonstrate important differences 
in migration behavior between metastatic breast cancer lines with different target 
organ specificity despite derivation from the same primary tumor and similar 
Rosetta-type poor prognosis gene expression. As 2D migration behavior is 
indicative of invasion and metastatic potential in vivo, these findings suggest 
important differences in the migration involved in the spread of metastatic breast 
cancer from breast tissue to lung or bone tissue.9 Although the MDA-231 
metastatic sublines and published gene expression profiles have been available 
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for over a decade, considerably little work has been done to characterize and 
compare differences in their in vitro phenotypes. Combined with published matrix 
invasion studies and the morphology studies presented in the previous aim, it is 
clear that metastatic tumor cells adopt altered phenotypes that distinguish them 
from metastatic cells in different target organs. Given the limited amount of 
published comparative data for genetically related metastatic lines, it is not yet 
clear if these differences are hallmark characteristics of a particular target organ 
preference or if they simply indicate heterogeneity in the primary tumor cells that 
go on to colonize metastatic tumors. Future work will include applying the 
methods in this aim to other available metastatic lines to identify characteristics 
unique to target organ preference or primary tumor tissue. Combined with 
published invasion studies, this aim demonstrates the novel conclusions that can 
be drawn from genetically related metastatic lines harvested through selection in 
a mouse model and advocates for the derivation of similar lines from other 
human tumors. 
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Chapter 4: A microfluidic platform for imaging cancer cell-endothelial 
interactions contributing to metastatic breast cancer matrix invasion 
 
4.1 Introduction 
Cell invasion of the extracellular matrix (ECM) is an important step in many 
normal and malignant processes in the body. For example, the wound healing 
cascade and inflammatory response both require well-controlled matrix invasion 
of fibroblasts and leukocytes, respectively.21,102,29 In human disease, cancer 
metastasis provides an example of abnormal and damaging tissue invasion, 
where cancer cells in circulation extravasate out of blood vessels to invade organ 
tissue and colonize a metastatic tumor.60,17 
 
Recent research in the field of metastatic cancer has aimed to identify important 
drivers of matrix invasion during extravasation. It is commonly thought that 
chemokines produced by stromal cells in a tissue create gradients that can drive 
cancer cells arrested in the vasculature to breach the capillary wall and invade 
tissue.8 Many important discoveries related to chemokine signaling driving 
metastatic cell matrix invasion have been achieved with the use of Transwell 
assays in which optically opaque, porous polycarbonate membranes are 
suspended above a culture plate well containing a chemoattractant.20 To 
summarize the type of results generated from this tool, recent studies involving 
Transwell chambers coated with matrigel have investigated how abundant tumor 
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stromal cell-secreted chemokines such as CXCL1, CCL2 as well as autocrine 
tumor cell-secreted VEGF may act as chemoattractants to drive matrix invasion 
of metastatic breast and ovarian cancer cells.7,83 
 
In addition to chemokine-driven gel invasion, cancer cells are also thought to 
interact directly with capillary endothelial cells via various adhesion molecules to 
gain entry to the underlying tissue.36,82 These interactions may not even require 
active communication between the cells, as some cells have even been shown to 
recognize and respond to fixed cells in culture.32,80 In addition to direct cell-cell 
interactions, endothelial cells may also influence cancer cell invasion indirectly 
through matrix deposition. It has been shown endothelial cells in culture deposit a 
significant layer of matrix on a culture surface and that gel invasion can be 
influenced by the gel protein composition and matrix fiber density.22,47,28,59 
 
Despite the recent momentum in unraveling chemokine-driven matrix invasion, 
there is relatively little quantitative in vitro evidence of the physical interactions 
between cancer cells and capillary endothelial cells or cell-secreted matrix 
related to metastatic cancer matrix invasion. This dearth of knowledge is due, in 
large part, to the lack of an appropriate tool to study these interactions, which 
require high-resolution imaging of the invasion process to generate conclusive 
and statistically justifiable results. While the Transwell gel invasion geometry is 
well-designed for studying matrix invasion in a diffusive chemoattractant gradient, 
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the construct is poorly suited for imaging, making the assay ineffective for 
investigating non-chemokine contributions to metastatic cancer cell matrix 
invasion. In addition, gel invasion in a Transwell insert is primarily quantified in 
terms of the number of cells that migrate through the gel to reach the membrane 
after a finite time period, giving no indication of more detailed metrics of 
invasion.20 
 
Microfluidic devices offer a unique alternative geometry to Transwell inserts that 
allows for imaging the matrix invasion process. For example, recent work has 
demonstrated the power of microfluidic platforms in studying cancer cell invasion 
of a matrix designed to replicate the microenvironment of metastatic lesion in 
bone tissue.85,12 Other microfluidic platforms have been designed to facilitate 
imaging of the invasion of tumor cell aggregates rather than individual cells and 
have even been designed to provide mathematically defined chemoattractant 
gradients as an alternative to the diffusive gradient observed in 
Transwells.106,63,31 While these studies have shown the utility of microfluidic 
devices in providing information about speed and depth of matrix invasion, the 
platforms often contain few gel interface regions on which to quantify invasion, 
yielding a small sample size for drawing conclusions about physical cell-cell or 
cell-matrix interactions at the gel surface. In addition, the intricate geometries of 
many platform designs preclude the use of standard immunohistochemistry 
staining protocols, which are necessary for identifying physical aspects of the 
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cancer cell-endothelial cell interactions involved in matrix invasion. 
 
In this study, we report the use of a microfluidic device to isolate contributions of 
inactive endothelial cell bodies and endothelial cell-secreted matrix proteins to 
the matrix invasion behavior of metastatic breast cancer cells from the line MDA-
MB-231. Each independent device includes large gel surface areas and contains 
media channels of appropriate size and geometry for effective 
immunohistochemistry analysis. Our methods reveal that, in absence of a 
chemoattractant gradient, metastatic breast cancer cells require a surface 
monolayer of endothelial cells for invasion of a type I collagen gel. To probe the 
mechanism of increased invasion in the presence of endothelial cells and to 
demonstrate the power of the microfluidic device in visualizing physical 
contributions to gel invasion, we studied cancer cell matrix invasion under 
conditions of decellularized endothelial cells as well as an endothelial monolayer 
treated with an ATP synthase inhibitor to halt cell activity. Through 
immunohistochemistry staining, our results confirm that endothelial cells deposit 
a fibronectin-rich matrix on the surface of a collagen gel but that the matrix alone 
does not promote cancer cell gel invasion to a degree that is physiologically 
relevant. Sodium azide-treated endothelial cells, however, were confirmed via 
imaging to remain on the collagen gel following treatment and resulted in 
significant matrix invasion of cancer cells. The combined results point to a 
mechanism of matrix invasion that does not rely entirely on active cell-cell 
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communication to drive cancer cell entry in a gel matrix in the absence of a 
chemokine gradient. In the future, specific cell surface integrins involved in this 
communication could be probed using this same device and pharmacological 
techniques. The results presented in this study demonstrate the power of our 
microfluidic matrix invasion platform over current Transwell and microfluidic gel 
invasion platforms in visualizing cell-cell and cell-matrix contributions to 
metastatic cancer invasion in the absence of a chemokine gradient. 
 
4.2 Methods 
Cell Culture and Reagents 
The invasive breast cancer line MDA MB 231 (MDA-231; ATCC, Manassas, VA) 
was cultured in phenol red-free Dulbecco's Modified Eagle's Medium (DMEM) 
supplemented with antibiotics (Gibco, Grand Island, NY) and 10% heat 
inactivated fetal bovine serum (HI FBS; Invitrogen, Carlsbad, CA; 56ºC for 30 
min). Microvascular endothelial cells (HUVEC; Chan Lab, Nanyang 
Technological University, Singapore) were cultured in endothelial cell medium 
with optimized HUVEC supplements (Lonza EGM2-MV). Cells were cultured at 
37ºC and 5% CO2 on plasma-treated tissue culture dishes and were detached 
from the surface using 0.05% trypsin (Gibco). 
 
Microfluidic Gel Invasion Model 
A microfluidic device was constructed by curing polydimethylsiloxane (PDMS) on 
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a silicon wafer mold containing a positive relief of a straight rectangular channel 
with five inlets and outlets and hexagonal posts that extend the height of the 
channel and divide the main channel into five equally spaced lanes (Fig. 4.1a). 
The resulting PDMS channel was fully encapsulated upon binding to a glass 
microscope slide using a plasma etcher. Dimensions of the main channel are 
4mm x 1.4mm x 100µm (LxWxH). The completed devices were stored at 80ºC 
for 24hr prior to use. Collagen gels were prepared over ice by diluting rat tail type 
I collagen (Corning, Corning, NY) to a final concentration of 3mg/mL with 10% by 
volume 1X PBS and deionized water. The pH was adjusted to pH 8.0 with 1N 
sodium hydroxide (NaOH), and the gels were polymerized by incubation at 37ºC 
for 30min. Gels were selectively polymerized in the 2nd and 4th lanes of the main 
channel by carefully injecting gel solution through the 2nd and 4th inlets and 
relying on surface tension between the hexagonal posts spaced 100µm apart to 
contain the solution in the desired lane (Fig. 4.1b). Following polymerization, the 
remaining lanes were filled with endothelial cell medium and stored at 37ºC. 
40,000 endothelial cells in normal culture medium were injected into the central 
channel of a microfluidic device containing collagen gel lanes and media. The 
device was oriented with the horizontal channel cross-section perpendicular to 
the ground to promote cell seeding along the vertical wall of one of the collagen 
gel lanes. Following a 30min incubation at 37ºC during which the remaining cell 
solution was kept on ice, cell seeding was repeated in the central channel. The 
device was again oriented perpendicular to the ground to promote seeding on the 
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opposite wall of collagen and incubated for 30min at 37ºC. The device was 
returned to normal orientation, all inlets and outlets were covered with endothelial 
cell media, and the device was incubated for 48h. 
 
Immunohistochemistry Staining for Vascular Endothelial (VE)-Cadherin and 
Deposited Fibronectin 
To prepare cells for VE-Cadherin staining, endothelial cells cultured on the 
collagen gel were washed with PBS and fixed in 4% paraformaldehyde (PFA) in 
PBS for 12min at room temperature. Device channels were flushed with PBS to 
wash out PFA, and cell membranes were permeabilized with the addition of 0.1% 
Triton X-100 for 10min at room temperature. Alternatively, cells in devices 
prepared for fibronectin staining were not fixed but were instead decellularized by 
incubation with a solution of 20mM ammonium hydroxide and 0.5% Triton X-100 
in PBS for 3min at room temperature. Following either decellularization or 
fixation/permeabilization, device channels were thoroughly washed in PBS and 
incubated in a blocking solution of 5% BSA-PBS overnight. The blocking solution 
was replaced with either a 1:400 dilution of primary VE-cadherin antibody (Cell 
Signaling Technologies, Danvers, MA) or a 1:200 dilution of primary human 
fibronectin antibody (Sigma-Aldrich, St. Louis, MO) in 5% BSA-PBS and stored at 
4ºC for 18hr. Primary antibody was removed with a PBS wash, and cells were 
stored in a 5% BSA-PBS blocking solution for 8hr at 4ºC. Blocking solution was 
then replaced with a solution containing 2µg/mL Hoechst 33342 (Molecular 
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Probes, Eugene, OR) along with secondary antibodies with appropriate host 
species reactivity in 1% BSA-PBS for 1hr at room temperature. In devices 
prepared for VE-cadherin staining, cells were incubated with a 1:200 dilution of a 
fluorescein-conjugated secondary antibody (Jackson ImmunoResearch, West 
Grove, PA); for fibronectin staining, a 10µg/mL dilution of Alexa Fluor 488-
conjugated secondary antibody was applied (Invitrogen, Carlsbad, CA). 
Antibody-labeled devices were stored at 4ºC in PBS and imaged using an 
Olympus FV1000 scanning confocal microscope with 405 and 488 nm excitation 
lines. 
 
Preparation Sodium Azide-Treated HUVECs 
To prepare a sodium azide-treated endothelial monolayer, HUVECs cultured on 
the collagen gel within the device were washed with PBS and incubated with 5% 
sodium azide in deionized water overnight at 4ºC. Device channels were washed 
thoroughly and stored overnight in PBS at 4ºC before addition of cancer cells. 
Devices containing sodium azide-treated HUVECs were imaged using an 
Olympus IX81 fluorescence microscope with a tetramethylrhodamine (TRITC) 
filter set. 
 
Quantifying Metastatic Breast Cancer Matrix Invasion 
MDA-231 cells were seeded in the device using the same seeding technique as 
described for HUVECs. Cancer cells were seeded in 4 different device 
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conditions: 1) directly on the type I collagen gel surface; 2) on top of the 
endothelial monolayer cultured on type I collagen gels; 3) directly on type I 
collagen gels following decellularization of endothelial monolayers cultured on 
the gel; and 4) on top of sodium azide-treated endothelial monolayers. 
Decellularization and sodium azide treatment methods are described in detail 
above. Cancer cells and endothelial cells (depending on the condition being 
studied) were imaged with the Olympus IX81 microscope through green 
fluorescent protein (GFP) and red fluorescent protein (RFP) filter sets both 
immediately after seeding and again after 24h of incubation at 37ºC. For 
analysis, the collagen gel lanes were divided into regions of interest (ROIs) that 
each include a volume of the 3D gel matrix corresponding to 3 adjacent gel 
surfaces separated by 100µm-wide PDMS posts. Each ROI was imaged multiple 
times at a variety of Z-planes to capture invading cells at all heights along the 
vertical collagen gel wall. Gel invasion in each ROI was measured as the 
maximum change in net displacement in a direction directly perpendicular to the 
gel surface. Invasion distance was quantified by directly comparing 0h and 24h 
images in ImageJ. 
 
Statistical Analysis 
In studying magnitude of matrix invasion, a total of n = 36 ROIs were compiled 
from 3 independent devices for each of the 4 device conditions. Pairwise 
comparisons between device conditions were tested for significance using 
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Matlab to perform a two-tailed t test with significance cutoffs of P = 0.01 or P = 
0.05.  
 
4.3 Results 
Design and Characterization of the Microfluidic Matrix Invasion Platform 
Evenly spaced pillars in the main channel of the microfluidic platform (Fig. 4.1a) 
enable flexibility in matrix gel patterning and a large collective gel surface area on 
which to quantify invasion. In applying the model to study cancer cell matrix 
invasion from a central channel into two separate lanes of type I collagen gel 
(Fig. 4.1b), this microenvironment design resulted in 38 separate 100μm x 
100μm gel surfaces grouped into 12 equally-sized regions of interest (ROIs) per 
device for statistical analysis (Fig. 4.2a–b). 
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Figure 4.1: Microfabricated matrix invasion model. (a) Top-down view of 
microfluidic device containing 5 inlets and outlets and 4 rows of hexagon posts. 
Central channel dimensions 4mm x 1.4mm x 100µm (LxWxH). (b) COMSOL 
rendering of the matrix invasion microenvironment built into the microfluidic 
device. Invasion model includes two lanes of type I collagen gel (blue), three 
lanes of endothelial growth medium containing 10% fetal bovine serum (FBS, 
gray), and endothelial cell monolayers (green) cultured on the vertically oriented 
inner faces of the collagen gels. (c) VE-Cadherin (green) and Hoechst (blue) 
staining to show the confluency of the endothelial monolayer cultured on a 
section of the collagen gel between PDMS posts (outlined in white). (d–e) 3D 
rendering of a complete Z-stack of endothelial cells cultured on a section of 
collagen gel. (d) Endothelial cells are confined to collagen gel surface and 
adjacent PDMS and glass boundaries. (e) VE-Cadherin staining at cell junctions 
along the full height of the gel. 
 
Endothelial cells cultured 48h in the device were stained for VE-Cadherin to 
investigate confluency along the vertically-oriented collagen gel wall. Confocal Z-
stacks of endothelial cells following immunohistochemistry (IHC) staining for VE-
cadherin revealed positive VE-cadherin staining at junctions between individual 
HUVEC nuclei (visualized with Hoechst) along the full height and width of 
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Figure 1. Microfabricated matrix invasion model. (A) Top-down view of microfluidic device containing 5 inlets and outlets and 4 rows of hexagon
posts. Central channel dimensions 4mm x 1.4mm x 100µm (LxWxH). (B) COMSOL rendering of the matrix invasion microenvironment built into
the microfluidic device. Invasion model includes two lanes of type I collagen gel (blue), three lanes of endothelial growth medium containing 10%
fetal bovine serum (FBS, gray), and endothelial cell monolayers (green) grown on the vertically-oriented inner faces of the collagen gels. (C) VE-
adherin (green) and Hoechst (blue) staining to show the confluency of the endothelial monolayer grown on a section of the collagen gel
between PDMS posts (outlined in white). (D-E) 3D rendering of a complete Z-stack of a endothelial cells grown on a section of collagen gel. (D)
Endothelial cells are confined to collagen gel surface and adjacent PDMS and glass boundaries. (E) VE-Cadherin staining at cell junctions along
the full height of the gel.
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exposed collagen gel surfaces (Fig. 4.1c,e). Confocal imaging also indicated that 
the HUVECs primarily grow on the vertical collagen gel surface but also extend 
from the gel to cover adjacent sections of PDMS and glass substrates forming 
the ceiling and floor of the microfluidic channel, respectively (Fig. 4.1d).  
 
Figure 4.2: Region of Interest (ROI) analysis of metastatic breast cancer matrix 
invasion. (a) Top-down view of gel invasion platform showing patterning of 2 
collagen gels lanes and a central lane containing HUVECs. (b) A magnified 
section of a one of the two collagen gel lanes containing a single ROI. ROI 
boundary extends across the width of 3 consecutive PDMS posts and collagen 
gel walls containing seeded cells. (c–f) MDA-231 cells (green) seeded along the 
collagen gel (white dashed line) imaged immediately after cancer cell seeding 
(c,e) and again 24h later (d,f). The magnitude of MDA-231 matrix invasion in a 
platform containing a HUVEC monolayer along the gel (c–d) was compared to 
MDA-231 matrix invasion in a platform lacking HUVECs (e–f). (Scale bar: 
100μm.)   
Figure 2. Region of Interest (ROI) analysis of
metastatic breast cancer matrix invasion. (A)
Top-down view of gel invasion platform showing
patterning of 2 collagen gels lanes and a central
lane containing HUVECs. (B) A magnified
section of a one of the two collagen gel lanes
containing a single ROI. ROI boundary extends
across the width of 3 consecutive PDMS posts
and collagen gel walls containing seeded cells.
(C-F) MDA-231 cells (green) seeded along the
collagen gel (white dashed line) imaged
immediately after cancer cell seeding (C,E) and
again 24h later (D,F). The magnitude of MDA-
231 matrix invasion in a platform containing a
HUVEC monolayer along the gel (C-D) was
compared to MDA-231 matrix invasion in a
platform lacking HUVECs (E-F). (Scale bar:
100μm.)
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Type I Collagen Gel Invasion of Metastatic Breast Cancer Cells is Enhanced 
in the Presence of a HUVEC Monolayer 
Top-down fluorescence images of cancer cells cultured on the collagen gel walls 
for 24h indicated a significantly decreased magnitude of matrix invasion in the 
absence of HUVECs (Fig. 4.2e–f). In fact, a quantitative analysis of matrix 
invasion distances revealed that MDA-231 cells invade less than 1μm past the 
collagen gel surface (0.61μm +/- 0.59μm) in the absence of endothelial cells (Fig. 
4.3). In the presence of a HUVEC monolayer, however, the cancer cell invasion 
distance increased significantly to an average of 26.7μm +/- 6.93μm (P = 
3.54x10-4, Fig. 4.2c–d).  
 
Figure 4.3: Magnitude of MDA-231 invasion of a type I collagen gel matrix over 
24h in varying HUVEC conditions. Compared to a platform lacking endothelial 
cells (“Gel Only” condition), the average distance of cancer cell matrix invasion 
was significantly larger in platforms containing live HUVECs, decellularized 
HUVECs, and sodium azide-treated HUVECs. Platforms containing live HUVECs 
and sodium azide-treated HUVECs also resulted in significantly larger 
magnitudes of cancer cell matrix invasion compared to platforms in which 
HUVECs had been decellularized prior to cancer cell seeding. Average values for 
n = 36 regions of interest (ROIs) from 3 independent devices for each condition. 
Error bars indicate standard error of the mean; **, P < 0.01 compared to Gel Only 
condition; ss, P < 0.01 between indicated pairs by Student’s t test.  
Figure 3. Magnitude of MDA-231 invasion of a type I collagen gel matrix over 24h in varying HUVEC conditions. Compared to
a platform lacking endothelial cells (“Gel Only” condition), the average distance of cancer cell matrix invasion was significantly
larger in platforms containing live HUVECs, decellul rized HUVECs, and sodium azide-tr ated HUVECs. Platforms containing
live HUVECs and sodium azide-treated HUVECs also resulted in significantly larger magnitudes of cancer cell matrix invasion
compared to platforms in which HUVECs had been decellularized prior to cancer cell seeding. Average values for n = 36
regions of interest (ROIs) from 3 independent devices for each condition. Error bars indicate standard error of the mean; **, P
< 0.01 compared to Gel Only condition; uu, P < 0.01 between indicated pairs by Student’s t test.
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Breast Cancer Gel Invasion is Enhanced in the Presence of Sodium Azide-
Treated Endothelial Cells but not Fibronectin-Rich Matrix Deposited by 
Decellularized HUVECs 
Confocal Z-stacks of the collagen gel following HUVEC decellularization and IHC 
staining for fibronectin revealed a dense fibronectin-rich matrix remaining on the 
gel surface in addition to sparse fibronectin throughout the 3D gel bulk (Fig. 
4.4a–b). In contrast, confocal images of a Hoechst nuclear stain (not shown) 
applied in conjunction with the IHC secondary antibody resulted in no significant 
signal above background intensity. MDA-231 cells seeded on top of this 
deposited fibronectin matrix exhibited significantly less collagen gel invasion 
(2.96μm +/- 0.58μm) than in devices containing the living HUVEC monolayer (P 
= 1.05x10-3; Fig. 4.3). The mean invasion distance was, however, statistically 
greater than that of the “Gel Only” control condition lacking either HUVECs or 
fibronectin matrix (P = 5.88x10-3).   
 
In studying the effect of present but physiologically inactive HUVEC cell bodies 
on cancer cell matrix invasion, fluorescence imaging of the microfluidic platform 
prior to cancer cell seeding revealed that HUVEC cells expressing red 
fluorescent protein (RFP) remained on the gel surface following sodium azide 
treatment and sufficient washing (Fig. 4.4c). Seeding MDA-231 on top of sodium 
azide-treated HUVECs in the device resulted in an average magnitude of cancer 
cell matrix invasion (14.0μm +/- 3.90μm) that was significantly greater than that 
  55 
of either the “Gel Only” control condition (P = 1.10x10-3) or the condition of 
decellularized HUVECs (P = 6.42x10-3; Fig. 4.3). 
 
Figure 4.4: Confocal imaging to confirm conditions of HUVEC decellularization 
and treatment with sodium azide prior to addition of MDA-231 cells within the 
microfluidic platform. Outlines of PDMS posts indicated by dotted white lines. (a) 
Immunohistochemical (IHC) staining for fibronectin (green) to show a fibronectin-
containing matrix remaining on the collagen gel surface following 
decellularization. (b) Top-down view of 3D Z-stack to show sparse fibronectin 
deposition throughout the collagen gel and dense fibronectin staining along the 
gel surface. (c) Top-down view of endothelial cell bodies (red) remaining along 
the surface of the collagen gel following sodium azide treatment and washing. 
(Scale bar: 50μm.). 
 
 
4.4 Discussion 
In this study, we have presented a microfluidic platform to facilitate staining and 
imaging of cell-cell and cell-matrix interactions that drive matrix invasion in 
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Figure 4. Confocal imaging to confirm conditions of
HUVEC decellularization and treatment with sodium
azide prior to addition of MDA-231 cells within the
microfluidic platform. Outlines of PDMS posts indicated
by dotted white lines. (A) Immunohistochemical (IHC)
staining for fibronectin (green) to show a fibronectin-
containing matrix remaining on the collagen gel
surface following decellularization. (B) Top-down view
of 3D Z-stack to show sparse fibronectin deposition
throughout the collagen gel and dense fibronectin
staining along the gel surface. (C) Top-down view of
endothelial cell bodies (red) remaining along the
surface of the collagen gel following sodium azide
treatment and washing. (Scale bar: 50μm.).
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absence of a chemokine gradient. As with other microfluidic models, our platform 
enables comparison of micron-scale invasion distance rather than the 
percentage migration typically reported for Transwells. This more detailed metric 
allows researchers to consider the relevance of invasion during specific 
physiological time periods.53,58  
 
One advantage of our microfluidic device is that it relies solely on surface tension 
between adjacent PDMS posts to contain matrix gels within individual channels, 
a design aspect that allows researchers to polymerize matrix protein gels in any 
of the 5, 4mm-long parallel and connected channels. Selective patterning of a gel 
in two separate internal lanes leaves both length-wise sides of each gel lane 
exposed for seeding and imaging of attached cells or deposited protein matrix 
and results in an expansive surface area on which to image matrix invasion 
compared to similar microfluidic devices. The novel flexibility in gel and cell 
patterning also allows this device to be easily modified to suit a variety of 
experimental applications. For example, alternative gel patterning in the 
outermost lanes creates a wider central channel, which may be of use in studying 
large-diameter tumor cell aggregates.34,42 Gel width can also be increased to 
study larger invasion depths by polymerizing matrix gels in multiple parallel 
lanes. Another advantage of our system is its straight, parallel channel design 
that facilitates straightforward immunohistochemistry (IHC) staining protocols. 
With the ability to selectively stain for structural proteins, our device may be 
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applied in the future to investigate a variety of deposited matrix proteins and cell 
surface adhesion molecules involved in extravasation.38,64  
 
 
Figure 4.5: Extending model applications to systems under flow. (a) COMSOL 
rendering of microfluidic matrix invasion model with constant-velocity flow 
through the 3 collagen-free lanes. (b) COMSOL rendering of velocity profile near 
the collagen gel interface (dotted line) in the microfluidic device at an input fluid 
velocity of 500μl/min. (c) Bright-field image showing stable collagen gels and 
HUVECs in a device with 500μl/min flow through each of the 3 gel-free lanes.  
 
Additional validation of the model has shown that the collagen gel lanes can 
withstand constant syringe pump-driven fluid flow through the central channel at 
volumetric flow rates of at least 500μl/min (Fig. 4.5), making the platform a useful 
tool for studying cell attachment or matrix invasion under shear stress.81,96 While 
our device was applied to investigate non-chemokine contributions to matrix 
invasion, the platform design is also well-suited for establishing chemokine 
gradients through the remaining gel-free channels. Through a combination of 
Figure S1. Extending m del applications to systems under fl w. (A) COMSOL rend ring of microfluidic matrix
invasion model with constant-velocity flow through the 3 collagen-free lanes. (B) COMSOL rendering of velocity
profile near the collagen gel interface (dotted line) in the microfluidic device at an input fluid velocity of 500μl/min.
(C) Bright-field image showing stable ollagen gels and HUVECs in a device with 500μl/min flow through each of
the 3 gel-free lanes.
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gradient-pump generated flow and diffusion through the stationary collagen gel 
lanes, our device geometry has been applied to visualize chemokine diffusion 
across endothelial monolayers (Fig. 4.6) and could be applied in the future to 
supply chemokine gradients for invading cells.32,79 
 
Figure 4.6: Extending model applications to matrix invasion in a soluble signal 
gradient using fluorescein isothiocyanate (FITC)-conjugated dextran as a 
surrogate chemokine. The flexibility in microenvironment design offered by this 
device leads to a variety of spatial options for establishing soluble signal 
gradients. (a) Top-down view of diffusion of FITC-dextran through lanes filled 
with collagen gel (outlined in blue) following injection into central inlet channel 
(Scale bar: 200μm.). (b) FITC-dextran injected into one of the outermost inlet 
channels in a device containing endothelial monolayers (red dotted lines) 
cultured on the inward-facing surfaces of two 3D collagen gel lanes. Compared 
to a device lacking HUVECs (a), diffusion throughout the device is limited is 
limited by the presence of the endothelial monolayer. (c) FITC-dextran injected 
through the center inlet channel in a platform designed with the same 
microenvironment as in (b) is initially contained within the central channel. (Scale 
bar: 200μm.). 
 
Physical cell-cell and cell-matrix interactions involved in metastatic cancer cell 
matrix invasion have been challenging to study because of the lack of an 
appropriate tool to both label cells and proteins and image the matrix invasion 
process. Here, we demonstrated these capabilities in our microfluidic platform 
through a novel investigation of physical interactions between metastatic cancer 
cells and endothelial cells that line capillary walls. The platform configuration 
Figure S2. Extending model applications to matrix invasion in a soluble signal gradient using fluorescein
isothiocyanate (FITC)-conjugated dextran as a surrogate chemokine. The flexibility in microenvironment
design offered by this device leads to a variety of spatial options for establishing soluble signal gradients.
(A) T p-down vi w f diffusion of FITC-dextran through la es filled with collagen gel (outlined in blue)
following injection into central inlet channel (Scale bar: 200μm.). (B) FITC-dextra injected into one of the
outermost inlet channels in a device containing endothelial monolayers (red dotted lines) grown on the
inward-facing surfaces of two 3D collagen gel lanes. Compared to a device lacking HUVECs (A), diffusion
throughout the device is limited is limited by the presence of the endothelial monolayer. (C) FITC-dextran
injected through the center inlet channel in a platform designe with the same micro nvironment as in (B) is
initially contained within the central channel. (Scale bar: 200μm.).
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used in this study resulted in complete lanes of polymerized collagen gel 
surrounded by channels of media on either side. This design choice mimics the 
configuration of gel invasion studies on Transwell membranes in which gels are 
suspended vertically between two media reservoirs. IHC staining of endothelial 
cells cultured on the gel revealed VE-cadherins located at junctions between 
neighboring endothelial cells. The presence of VE-cadherin at cell junctions is 
characteristic of an endothelial monolayer and is an important component of 
microvessel integrity in vivo.33,24 These results suggests that our system models 
cancer cells migrating through a monolayer of endothelial cells before invading 
an ECM protein gel. 
 
Compared to cancer cells in a device lacking endothelial cells, cancer cells 
seeded on top of the endothelial monolayer showed significant invasion of the 
collagen gel over 24hr, which is the time frame under which most metastatic 
cancer cells in circulation are assumed to complete extravasation in vivo.72,37 In 
the investigation to reveal non-chemokine driven mechanisms for this finding, 
positive IHC staining for fibronectin on the gel surface following endothelial 
decellularization confirmed previous reports that endothelial monolayers deposit 
a fibronectin-containing matrix.22 The lack of positive stain following incubation 
with Hoechst (not shown) confirmed the removal of endothelial cell bodies.25 A 
gene expression profile study from Minn et al. suggests that the MDA-MB-231 
used in our study express both more integrins and matrix metalloproteinases for 
  60 
the deposited fibronectin than for underlying type I collagen gel.61,3 However, 
while the mean invasion depth of a fibronectin-coated gel compared to the 
endothelial cell-free control was statistically significant with P < 0.01, the ~2μm 
difference accounts for less than 20% of a breast cancer cell diameter and likely 
does not represent a physiologically relevant magnitude of cancer cell matrix 
invasion.41 
 
Sufficient cancer cell matrix invasion of at least 1 cell diameter was seen, 
however, when cancer cells were seeded on top of endothelial cells treated with 
sodium azide to terminate cell function while leaving endothelial cell bodies 
attached to the gel surface.62 Our results suggest that metastatic cancer cells are 
able to exploit aspects of inactive endothelial cell membranes to gain entry into 
the collagen matrix without active and reciprocal interaction from the endothelial 
cells. This finding may have important implications for developing drugs targeted 
at metastatic cancer matrix invasion, as our results have shown that the process 
may involve structural cell-cell interactions that do not rely on soluble signals or 
active endothelial cells.67,43 This platform is well-suited to carry out future studies 
to identify the specific membrane proteins on inactive endothelial cells that 
cancer cells utilize in gaining entry to an ECM gel.11,27,4,12  
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Chapter 5: Future Work and Recommendations 
In this work, we identified key differences in in vitro behavior between metastatic 
breast cancer cells with different preferences in metastatic target organ. We have 
also presented a microfluidic matrix invasion model that has identified novel 
endothelial cell contributions to in vitro cancer cell extravasation. 
 
In Chapter 2, we characterized the differences in morphology between metastatic 
breast cancer cells with different metastatic organ preferences. We found that 
tumor cells from different metastatic niches have significant differences in cell 
shape, actin fiber alignment, and roundness - metrics correlated with metastatic 
potential and cell function in vivo. Performing a similar study on major cell 
populations from the preferred metastatic niche may provide an explanation for 
why metastatic cells derived from the same primary tumor are observed to have 
significantly different morphologies after metastasis. In addition, the conclusions 
from this work may be strengthened by future work to vary culture substrate and 
media to identify whether the differences in morphology are preserved across 
culture conditions. We have already begun preliminary work to adapt protocols 
from Aim 1 to answer this question. Specifically, we have cultured and imaged 
metastatic breast cancer cells on polyacrylamide gels rather than glass, as it is 
known that extracellular matrix stiffness is linked to chemoresistance, the 
development of cancer stem cell-like properties in metastatic tumors, and the 
onset of an epithelial to mesenchymal transition in cancer cells.86 Additional 
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alterations to protocol could also include varying growth factors present in the 
culture media, as studies have shown a link between metastatic organ 
preference and growth factors secreted at the pre-metastatic niche.65,92,74 
 
In Chapter 3, we characterized the differences in chemokinesis and focal 
adhesion arrangement between metastatic breast cancer cells with different 
metastatic target organ preference. We found that the cell lines differ in important 
migration metrics such as motility and speed but retain similar directionality. We 
also demonstrated that representative cells from the 3 lines exhibit different 
arrangements in vinculin distribution despite similar expression of vinculin mRNA 
in the published gene expression profiles. In the future, A comparison of gene 
expression signatures between the tumor lines could identify genes responsible 
differences in migration behavior between these 3 related lines. Using simple 
tools like the Ibidi 3D Chemotaxis Chamber and migration protocols detailed in 
this work, it is also possible to perform a high-throughput study of drugs targeted 
against the pro-migration proteins expressed in these metastatic cell lines. 
 
In an effort to compare migration behavior in a geometry that better approximates 
that of in vivo tissue invasion, another future recommendation for this study 
would be to apply a similar protocol to quantify chemokinesis through a 3D 
extracellular matrix protein gel. The Ibidi 3D Chemotaxis chamber is well-suited 
for this analysis, as its channel dimensions and top-down imaging capability 
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allow for quantifying 2D speed, motility, and directionality of cells suspended in a 
3D matrix. We have begun preliminary work on this study by adapting the 
protocols of Aim 2 to suspend cancer cells in a 3D type I collagen gel matrix 
within the Ibidi platform and confirm viability of suspended cells prior to 
application of serum to induce chemokinesis. 
 
In Chapter 4, we demonstrated a novel platform that facilitates the isolation and 
imaging of cell-cell and cell-matrix interactions driving matrix invasion. Applying 
the model to metastatic cancer cell matrix invasion yielded important findings 
regarding the interactions between cancer cells and endothelial cell bodies that 
facilitate invasion in the absence of chemokine gradients or actively 
communicating endothelial cells. The expansive gel surface areas and the ease 
with which IHC protocols can be adapted for use in this device make it a novel 
alternative to Transwell assays and the majority of currently available microfluidic 
invasion platforms. In addition to the utility of this model in elucidating 
mechanisms of cancer matrix invasion, the flexibility in gel and cell patterning 
and the stability of the system under flow lend this platform to applications 
extending beyond cancer to include immune response and vascular flow.33,23 
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